Drug profile

The FDA adverse-event record for Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live

Name: Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live - FDA Animal Adverse Event Reports
Creator: PlainBreed
License: https://creativecommons.org/publicdomain/zero/1.0/

304 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live. See the species affected, top reactions, and outcomes below.

304
adverse-event reports: 9.5%
death-coded share: Dog
most-reported species: 101
Vomiting - top reaction

Compiled by PlainBreed Editorial, Pet Health Editorial Team

Verify with FDA CVM →

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

304

Total Reports

Deaths Reported

9.5%

Death Rate

Active Ingredients

Canine Adenovirus Type 2,Toronto A/26/61,LiveCanine Distemper,Vcp258,VectorCanine Parainfluenza Virus,D-008,LiveCanine Parvovirus,780916,Live

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 304

Most Affected Breeds

Retriever - Labrador 24

Retriever - Golden 23

Chihuahua 18

Terrier - Yorkshire 16

Crossbred Canine/dog 13

Pit Bull 13

Shih Tzu 10

Dachshund (unspecified) 9

Poodle - Toy 9

Poodle - Miniature 9

Most Reported Reactions

Vomiting 101

Lethargy (see also Central nervous system depression in 'Neurological') 67

Diarrhoea 55

Injection site pain 35

Anorexia 26

Other abnormal test result NOS 26

Lethargy (see also Central nervous system depression in Neurological) 24

Neutrophilia 22

Leucocytosis NOS 21

Death 19

Seizure NOS 19

Fever 19

Outcome Breakdown

Outcome Unknown

122 (40.0%)

Recovered/Normal

116 (38.0%)

Ongoing

37 (12.1%)

Died

18 (5.9%)

Euthanized

12 (3.9%)

Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live Adverse Event Insights

304 reports name Canine Adenovirus Type 2,Toronto A/26/61,Live + Canine Distemper,Vcp258,Vector + Canine Parainfluenza Virus,D-008,Live + Canine Parvovirus,780916,Live; 29 recorded a death outcome (9.5% of reported events, not a population-level mortality rate). Active ingredients: Canine Adenovirus Type 2,Toronto A/26/61,Live, Canine Distemper,Vcp258,Vector, Canine Parainfluenza Virus,D-008,Live, Canine Parvovirus,780916,Live. Administration routes: Subcutaneous, Unknown.

By species: Dog (304 reports). By breed: Retriever - Labrador (24), Retriever - Golden (23), Chihuahua (18).

Leading clinical signs: Vomiting (101), Lethargy (see also Central nervous system depression in 'Neurological') (67), Diarrhoea (55), Injection site pain (35). Outcome, 305 coded reports: Outcome Unknown leads at 40.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.